跳至主要内容
临床试验/NCT04949880
NCT04949880进行中(未招募)不适用

The Efficacy and Safety Study for Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis Using Neurovascular Drug-Eluting Balloon Dilatation Catheter: A Prospective Multicentre Single-arm Trial

Zhejiang Zylox Medical Device Co., Ltd.11 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2021年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
132
试验地点
11
主要终点
Restenosis rate of the target lesion

研究概览

简要总结

This is a trial designed to test the efficacy and safety of the Neurovascular Drug-Eluting Balloon Dilatation Catheter.

详细描述

This is a prospective multicentre single-arm trial conducted by 11 centers in mainland China. Approximately 132 subjects with symptomatic intracranial atherosclerotic stenosis receive endovascular treatment using the neurovascular drug-eluting balloon dilatation catheter designed by Zylox.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 80 years, any gender;
  • Subject has symptomatic intracranial atherosclerotic stenosis that the degree of the artery stenosis is between 70% and 99% diagnosed by intracranial angiography;
  • The target stenotic artery locates in Internal Carotid Artery (intracranial segment), Middle Cerebral Artery (M1, M2), Basilar Artery, Vertebral Artery (intracranial segment);
  • Intracranial artery stenosis requiring interventional treatment is a single lesion;
  • Subject has at least two atherosclerosis risk factors including history or present hypertension, diabetes, hyperlipidemia, smoking, age>45;
  • modified Rankin Scale(mRS) score≤2 before enrollment;
  • Subject or guardian is able to understand the purpose of study, agree to provide follow-up data and has provided written informed consent.

排除标准

  • History of acute ischemic stroke within 2 weeks;
  • History of intracranial hemorrhage (including intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months;
  • Hypertension uncontrolled by medicine (Systolic pressure≥180 mmHg or diastolic pressure≥110 mmHg continuously);
  • Combined with the intracranial tumor, aneurysm or intracranial arteriovenous malformation;
  • The length of intracranial artery stenosis >10mm and extremely angulated >90°, which indicated by angiography;
  • History of stent intervention within the target lesion;
  • Allergic to heparin, sirolimus (i.e. rapamycin), contrast agents, aspirin, clopidogrel, anesthetics;
  • History of gastrointestinal hemorrhage within 6 months before signing the informed consent form, which is unable to receive antiplatelet therapy;
  • Platelet (PLT)<90*10^9/L;
  • Creatinine>250 umol/L;
  • International Normalized Ratio (INR)>1.5;
  • Female subject who is pregnant or breast-feeding, or who has a pregnancy plan within 12 months;
  • Expected life <12 months;
  • Unable to cooperate with or tolerate the interventional surgery;
  • Subject who has participated in other drug or device clinical trials or hasn't reached the primary end point;
  • Angiography indicates intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis;
  • Angiography indicates the vascular path is tortuous, the experimental device is difficult to reach the target position or be retracted;
  • Other circumstances judged by researchers that are not suitable for enrollment.

结局指标

主要结局

Restenosis rate of the target lesion

时间窗: 180+60 days

Subjects receive Digital Subtraction Angiography (DSA) / Computed Tomography Angiography (CTA) examination in 180 days to analyze whether the degree of stenosis is greater than or equal to 50%, if so, the target lesion restenosis happens.

次要结局

  • Success rate of surgery(Intraoperation)
  • Average stenosis degree of the target lesion(180+60 days)
  • Success rate of device(Intraoperation)

研究者

发起方
Zhejiang Zylox Medical Device Co., Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验